Overview

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect. We also hypothesize that our mechanistic studies will yield biomarkers that may herald disease recurrence or progression following alterations in the recovery of immune cells in the skin and/or bronchial lavage or blood.
Phase:
Phase 2
Details
Lead Sponsor:
Paul Szabolcs
Treatments:
Alemtuzumab
Antibodies
Cyclophosphamide
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Rituximab
Thiotepa